CD274 and non-small cell lung carcinoma: Immunotherapy with anti-programmed death-(ligand) 1 (PD-(L)1) immune checkpoint inhibitors (ICIs) has also significantly improved the survival of NSCLC patients without oncogenic drivers [3,4,5,6,7,8,9].